ABVC BIOPHARMA INC (ABVC)
US00091F3047 - Common Stock
ABVC BIOPHARMA INC
NASDAQ:ABVC (1/14/2025, 8:21:42 PM)
Premarket: 0.5207 +0.01 (+0.97%)0.5157
-0.01 (-2.7%)
Company Profile
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 16 full-time employees. The company went IPO on 2004-11-09. The firm develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. The company has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). The company is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The firm develops drugs and medical devices derived from plants.
Company Info
ABVC BIOPHARMA INC
44370 Old Warm Springs Blvd
Fremont CALIFORNIA
P: 15106680881
CEO: Howard Doong
Employees: 18
Website: https://abvcpharma.com/
ABVC News
a day ago - TheNewswire.comAiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing FeesLicensing Fees From AiBtl and Strategic Partners Now Total $696,000, Bolstering Confidence in AiBtl’s Plans
a day ago - NewMediaWireAiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing FeesSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
2 days ago - TheNewswire.comABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price RequirementFREMONT, CA - January 13, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, is pleased to announce that Nasdaq has granted the Company an additional 180-day grace period, until July 7, 2025, to regain compliance with the Nasdaq Capital Market’s minimum $1.0 bid price per share requirement.
2 days ago - NewMediaWireABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price RequirementSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
8 days ago - NewMediaWireABVC BioPharma and ForSeeCon: An Update on Alliance's Ophthalmology-Related ProductsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
13 days ago - NewMediaWireABVC BioPharma Secures an Additional Patent for ADHD Treatment, in Addition to the Granted U.S. and Australian Patents, Moving Forward to the Global Patent Map of $32.14 Billion Potential MarketSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC Twits
Here you can normally see the latest stock twits on ABVC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
